Share Email Print
cover

Proceedings Paper

Preliminary clinical data on a new photodynamic therapy photosensitizer: 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH) for treatment of obstructive esophageal cancer
Author(s): Thomas J. Dougherty; R. K. Pandey; Hector R. Nava; Judy L. Smith; Harold O. Douglass; Stephen B. Edge; David A. Bellnier; Linda O'Malley; Michele Cooper
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Limited therapeutic options exist when chest wafl recurrence from breast cancer progresses despite standard salvage treatment. As photodynamic therapy offers excellent response for cutaneous lesions this may be a possible indication for PDT. A total of 1 02 treatment fields were illuminated on 9 women with biopsy proven chest wall recurrence of breast cancer which was progressing despite salvage surgery, radiation, and chemo-hormonal therapy. PDT consisted of outpatient IV infusion ofPhotofrmn at 0.8 mg/kg followed 48 hours later by illumination at 140-170 J/cm2 via a KTP Yag laser coupled to a dye unit. No patient was lost to follow up. At 6 months post PDT; complete response, defined as total lesion elimination was 89%, partial response 8%, and no response 3%. No photosensitivity was seen and no patient developed scarring, fibrosis, or healing difficulties. Low dose Photofrmn induced PDT is very active against chest wall lesions. Despite fragile and heavily pre-treated tissues, excellent clinical and cosmetic outcome was obtained. PDT is an underutilized modality for this indication.

Paper Details

Date Published: 29 March 2000
PDF: 3 pages
Proc. SPIE 3909, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy IX, (29 March 2000); doi: 10.1117/12.379876
Show Author Affiliations
Thomas J. Dougherty, Roswell Park Cancer Institute (United States)
R. K. Pandey, Roswell Park Cancer Institute (United States)
Hector R. Nava, Roswell Park Cancer Institute (United States)
Judy L. Smith, Roswell Park Cancer Institute (United States)
Harold O. Douglass, Roswell Park Cancer Institute (United States)
Stephen B. Edge, Roswell Park Cancer Institute (United States)
David A. Bellnier, Roswell Park Cancer Institute (United States)
Linda O'Malley, Roswell Park Cancer Institute (United States)
Michele Cooper, Roswell Park Cancer Institute (United States)


Published in SPIE Proceedings Vol. 3909:
Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy IX
Thomas J. Dougherty, Editor(s)

© SPIE. Terms of Use
Back to Top